Abstract | BACKGROUND: METHODS: We carried out a systematic review and meta-analysis of patients with head and neck cancer who were treated with rebamipide mouthwash. We searched PubMed, EMBASE, and Cochrane Central Register of Controlled Trials (CENTRAL), and the World Health Organization (WHO) International Clinical Trial Registry Platform. The primary outcome was the incidence of severe oral mucositis, and secondary outcomes were time from treatment start to onset of oral mucositis, the response rate of radiotherapy, and any adverse events. RESULTS: CONCLUSIONS:
Rebamipide mouthwash is effective in the prevention of severe mucositis and stomatitis. However, evaluation of adverse events in observational studies are needed.
|
Authors | Shinsuke Akagi, Takashi Fujiwara, Mai Nishida, Akiko Okuda, Yuka Nagao, Toshikatsu Okuda, Hidenori Tokuda, Kazunobu Takayanagi |
Journal | Journal of pharmaceutical health care and sciences
(J Pharm Health Care Sci)
Vol. 5
Pg. 16
( 2019)
ISSN: 2055-0294 [Print] England |
PMID | 31367460
(Publication Type: Journal Article)
|